Explorative analysis of the immunmodulatory capacities of apathogenic Escherichia coli Nissle 1917 in patients with rhinoconjunctivitis due to grass pollen allergy.

Prof. Dr. med. Margitta Worm0 个研究点目标入组 34 人开始时间: 2008年10月29日最近更新: 2022年5月30日

试验速览

暂无简介。

•Age between 18 and 65 years (women and men)
•Clinical relevat grass pollen allergy with required treatment of the rhinoconjunctivitis symptoms since at least 2 years
•Positive skin prick test (SPT) to grass pollen extract
•Positive specific IgE towards grass pollen (at least CAP class 2)
•Written inform consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Perennial rhinoconjunctivitis
•Chronic diarrhoe and other existing severe gastrointestinale diseases
•Asthma bronchiale (Gina II - IV)
•Use of Mutaflor® 12 weeks before the start of the trial
•Use of antibiotics towards gram negative bacteria 4 weeks before the start of the trial
•Specific immunotherapy to grass pollen 6 months before the start of the trial
•Current specific immunotherapy to any allergen
•Female patients: pregnancy and lactation period
•Severe cardiovascular diseases and metabolic disorders, autoimmune diseases or other systemic inflammatory disorders

发起方

Prof. Dr. med. Margitta Worm